Navigation Links
Perrigo Receives FDA Tentative Approval For Generic Equivalent To Prandin(R)
Date:7/19/2013

ALLEGAN, Mich., July 19, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received tentative approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for repaglinide tablets, the generic equivalent to Prandin® Tablets (repaglinide tablets).

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Prandin® tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of approximately $250 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This approval shows the talent and expertise of our R&D and regulatory affairs departments. This is another example of Perrigo's commitment to bring new products to market and deliver on its mission to provide quality, affordable healthcare to consumers."

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico'/>"/>

SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
2. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
3. Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications
4. Perrigo Reports Record Revenue and Adjusted Earnings
5. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
6. Perrigo Company To Present At The Barclays Global Healthcare Conference
7. Perrigo Company To Present At The RBC Global Healthcare Conference
8. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
9. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
10. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
11. Perrigo Confirms FDA Approval For Testosterone Gel 1%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... clinicians and researchers to advisory roles. The panel ... Relmada,s development programs and efforts to advance the ... chronic pain. They bring expertise in a range ...
(Date:3/5/2015)... 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss year-end 2014 financial ... programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation ... TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery ... 2015. To participate in the call, interested parties ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
... - Results suggest pirfenidone may provide meaningful clinical benefit ... efficacy and safety reported -- Conference Call and Webcast ... DIEGO, May 19 InterMune, Inc. (Nasdaq: ... 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic ...
... that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... placebo in patients with Bipolar I Disorder. Results of ... medical meeting. Bipolar Disorder is a brain disorder ... and ability to function. It is often characterized by ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:3/5/2015)... 06, 2015 In 2014, the FDA ... AstraZeneca tops the list scoring 4 drug approvals in ... of all FDA approved drug products, followed by oncology ... as anti-PCSK9, anti-PD1 and CDK inhibitors keep on attracting ... the FDA to treat metastatic melanoma, and at present, ...
(Date:3/5/2015)... Alachua, FL (PRWEB) March 05, 2015 ... technology company focused on the peripheral nerve repair market, ... quarter ended December 31, 2014 compared to $2.98 million ... execution of its growth strategies. , “Our strong ... of our peripheral nerve repair products which is driving ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
(Date:3/5/2015)... March 05, 2015 TCS Healthcare Technologies ... for the population health management arena, is pleased to ... management software, ACUITY Advanced Care™ (ACUITY) version 7.20. The ... performance and the advantages of automation. , The webinar, ... will be led by Jeff Frater, RN, BSN, Director ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
Breaking Medicine News(10 mins):Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2
... Leading ... smell and taste , ... N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman , senior partner of leading national ... his firm has filed a civil lawsuit against the manufacturer of the popular Zicam nasal ...
... Calif., July 7 Today, the Service Employees International Union ... filed a motion with U.S. District Court to hold the ... Supportive Services (IHSS) workers by $2 per hour in defiance ... that the State feels it can simply ignore a U.S. ...
... Infants and young children treated with heart drugs get the ... medication errors more often than older children, according to research ... July 6 in Pediatrics . While the ... the age of 1, they say children of all ages ...
... XTENT, Inc. (Nasdaq: XTNT ) today announced that ... to take place at 9:00 a.m. Pacific Time on Thursday, July ... Pacific Time on August 3, 2009. , , ... directors had unanimously approved a Plan of Complete Liquidation and Dissolution ...
... , SAN FRANCISCO, July 7 AMB Property Corporation(R) (NYSE: ... of industrial real estate, today announced that it has fully ... AMB Hausbruch Industrial Center in Hamburg to BSN medical GmbH, ... July 1, 2009, renews BSN medical,s previous commitment to 210,000 ...
... ,PROVIDENCE, R.I. [Brown University] Fueling the debate over ... repressed memory, Brown University political scientist Ross Cheit is ... is how to prove whether the memories of trauma, ... then resurface later in life. Cheit,s paper, co-authored by ...
Cached Medicine News:Health News:New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product 2Health News:Contemptible: Governor, State Officials Defy Court Order to Stop Home Care Cuts, Says SEIU 2Health News:Wrong dose of heart meds too frequent in children 2Health News:XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders 2Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 2Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 3Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 4Health News:Brown professor continues debate over recovered memory 2
... Your patient will be more comfortable, and ... tube stabilization more secure and to avoid ... and untying of twill ties, consider the ... and neonate/infant sizes, the narrow fastener tabs ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... kit features a patented Per-fit™ flexible PVC ... a low-profile cuff specifically designed to reduce ... the patients anatomy. The kit s unique ... tube snugly, allowing for an easier transition ...
Medicine Products: